265 related articles for article (PubMed ID: 30982895)
21. Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants.
Leader S; Yang H; DeVincenzo J; Jacobson P; Marcin JP; Murray DL
Value Health; 2003; 6(2):100-6. PubMed ID: 12641860
[TBL] [Abstract][Full Text] [Related]
22. The Long-Term Healthcare Utilization and Economic Burden of RSV Infection in Children ≤5 Years in Japan: Propensity Score Matched Cohort Study.
Chirikov V; Botteman M; Simões EAF
Clinicoecon Outcomes Res; 2022; 14():699-714. PubMed ID: 36389101
[TBL] [Abstract][Full Text] [Related]
23. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
24. Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy.
Escobar GJ; Masaquel AS; Li SX; Walsh EM; Kipnis P
BMC Pediatr; 2013 Jun; 13():97. PubMed ID: 23782528
[TBL] [Abstract][Full Text] [Related]
25. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants.
O'Shea TM; Sevick MA; Givner LB
Pediatr Infect Dis J; 1998 Jul; 17(7):587-93. PubMed ID: 9686723
[TBL] [Abstract][Full Text] [Related]
26. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000.
Leader S; Kohlhase K
J Pediatr; 2003 Nov; 143(5 Suppl):S127-32. PubMed ID: 14615711
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology of Medically Attended Respiratory Syncytial Virus Lower Respiratory Tract Infection in Japanese Children, 2011-2017.
Simões EAF; Botteman M; Chirikov V
J Infect Dis; 2024 Apr; 229(4):1112-1122. PubMed ID: 37625899
[TBL] [Abstract][Full Text] [Related]
28. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
[TBL] [Abstract][Full Text] [Related]
30. Healthy Late-preterm infants born 33-36+6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization.
Helfrich AM; Nylund CM; Eberly MD; Eide MB; Stagliano DR
Early Hum Dev; 2015 Sep; 91(9):541-6. PubMed ID: 26186560
[TBL] [Abstract][Full Text] [Related]
31. Chronic manifestations of respiratory syncytial virus infection in premature infants.
Greenough A; Broughton S
Pediatr Infect Dis J; 2005 Nov; 24(11 Suppl):S184-7, discussion S187-8. PubMed ID: 16378044
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
[TBL] [Abstract][Full Text] [Related]
33. Incidence of respiratory syncytial virus bronchiolitis in hospitalized infants born at 33-36 weeks of gestational age compared with those born at term: a retrospective cohort study.
Greenberg D; Dagan R; Shany E; Ben-Shimol S; Givon-Lavi N
Clin Microbiol Infect; 2020 Feb; 26(2):256.e1-256.e5. PubMed ID: 31181285
[TBL] [Abstract][Full Text] [Related]
34. Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up.
Valkonen H; Waris M; Ruohola A; Ruuskanen O; Heikkinen T
Allergy; 2009 Sep; 64(9):1359-65. PubMed ID: 19416146
[TBL] [Abstract][Full Text] [Related]
35. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
Marchetti A; Lau H; Magar R; Wang L; Devercelli G
Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants-The SPRING Study.
Carbonell-Estrany X; Pérez-Yarza EG; García LS; Guzmán Cabañas JM; Bòria EV; Atienza BB;
PLoS One; 2015; 10(5):e0125422. PubMed ID: 25955487
[TBL] [Abstract][Full Text] [Related]
37. Respiratory syncytial virus risk factors in late preterm infants.
Lanari M; Silvestri M; Rossi GA
J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
[TBL] [Abstract][Full Text] [Related]
38. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
Krilov LR; Fergie J; Goldstein M; Brannman L
Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
[TBL] [Abstract][Full Text] [Related]
39. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
Resch B; Egger B; Kurath-Koller S; Urlesberger B
Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
[TBL] [Abstract][Full Text] [Related]
40. Population-Attributable Risk of Risk Factors for Recurrent Wheezing in Moderate Preterm Infants During the First Year of Life.
Blanken MO; Korsten K; Achten NB; Tamminga S; Nibbelke EE; Sanders EA; Smit HA; Groenwold RH; Bont L;
Paediatr Perinat Epidemiol; 2016 Jul; 30(4):376-85. PubMed ID: 27199198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
